Arpida sells iclaprim to Acino and prepares for Evolva merger
This article was originally published in Scrip
Arpida has sold its diaminopyrimidine antibiotic iclaprim to fellow Swiss firm Acino for CHF2.1 million ($2.05 million). Development of the drug, which Arpida licensed from Roche and was developing under the name Mersarex, ran aground after the EU's CHMP issued a negative opinion last month (scripnews.com, October 26th, 2009). In the US, the FDA issued a complete response letter requiring further clinical trials which the company deemed to be too costly. An earlier FDA panel had recommended against its approval saying that Arpida had failed to show non-inferiority to linezolid (Pfizer's Zyvox).
You may also be interested in...
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.